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Abstract: Achromobacter xylosoxidans can cause chronic infections in the lungs of patients with cystic
fibrosis (CF) by adapting to the specific environment. The study of longitudinal isolates allows to
investigate its within-host evolution to unravel the adaptive mechanisms contributing to successful
colonization. In this study, four clinical isolates longitudinally collected from two chronically infected
patients underwent whole genome sequencing, de novo assembly and sequence analysis. Phenotypic
assays were also performed. The isolates coming from one of the patients (patient A) presented
a greater number of genetic variants, diverse integrative and conjugative elements, and different
protease secretion. In the first of these isolates (strain A1), we also found a large deletion in the mutS
gene, involved in DNA mismatch repair (MMR). In contrast, isolates from patient B showed a lower
number of variants, only one integrative and mobilizable element, no phenotypic changes, and no
mutations in the MMR system. These results suggest that in the two patients the establishment of a
chronic infection was mediated by different adaptive mechanisms. While the strains isolated from
patient B showed a longitudinal microevolution, strain A1 can be clearly classified as a hypermutator,
confirming the occurrence and importance of this adaptive mechanism in A. xylosoxidans infection.
Keywords: lung infection; opportunistic pathogen; bacterial evolution; comparative genomics;
clonal diversification
1. Introduction
Cystic fibrosis (CF) is strictly linked with chronic bacterial respiratory infections; in fact, airways
infection and the ensuing inflammation account for the majority of morbidity and mortality of CF
patients [1]. Achromobacter xylosoxidans is an opportunistic pathogen in patients with CF, where this
microorganism can survive for a long time in both lower and upper airways [2]. Infection results either
from acquisition of bacteria present in the environment or from direct or indirect transmission [3,4]
and is usually complicated by the intrinsic and acquired multidrug resistance traits carried by this
microorganism. Chronic lung infection byA. xylosoxidans has been associated with decline in respiratory
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function, increased frequency of exacerbations and lung inflammation [3,5,6]. Nevertheless, very
little is known about the pathogenic mechanisms allowing A. xylosoxidans to colonize and persist in
CF airways.
Pathogenic mechanisms of other CF pathogens are well-known; in particular, Pseudomonas
aeruginosa has been extensively studied, due to its high incidence in CF patients and the difficult—in
many cases impossible—eradication. One of the main mechanisms favouring the persistence
of P. aeruginosa in the airways of CF patients is the ability to genetically adapt during chronic
infection. In particular, short-term adjustments are believed to be the result of regulatory alterations
in gene expression whereas long-term adaptation is the result of the accumulation of pathoadaptive
mutations [7]. Consequently, the potential and speed for bacterial pathogens to genetically adapt to
the host immune system and drug therapies may be determined by the within-host mutation rate [8].
Interestingly, the generation rate of mutations can be accelerated due to mutations in the DNA mismatch
repair system, giving rise to hypermutation events and to clonal diversification within the host [9].
The adaptation of bacteria to a heterogeneous and changing environment can promote selection of
hypermutable strains. Since A. xylosoxidans is an emerging pathogen, its pathoadaptive evolution and
its impact in relation to chronic infections is still not clear. In this work we studied longitudinally
collected clinical isolates of A. xylosoxidans to unravel the adaptive mechanisms contributing to its
successful colonization of CF lungs.
2. Results
We sequenced the genome of four A. xylosoxidans isolates longitudinally collected from sputum
samples of two CF patients. Two isolates were collected from each patient: in 2005 and 2008 from
patient A, and in 2008 and 2014 from patient B. Genotypic relatedness was verified by checking core
genome similarities: Isolates coming from each patient showed 87% similarity with the respective
longitudinal isolate. Both patients had been chronically infected for 9 years: The year of first A.
xylosoxidans isolation was 1996 and 1999 for patients A and B, respectively. The general information
on de novo assembly of each genome is presented in Table 1. The assembly lengths varied between
6.6–6.9 Mbp and the GC-content varied between 67.63–68.09%, which is comparable to the published
reference genome NH44784-1996 [10].
Table 1. Information on the de novo assembly of each genome. Longitudinal isolates are numbered (1,
2) following the time of isolation.
Patient Isolate GenomeSize (bp)
GC-Content
(%)
No.
Contigs N50
Mean
Coverage
Depth
(x)
No.
Coding
Sequences
Mapping
Reads
(%)
A A1 6913734 68.09 291 78688 66 6359 98.3
A A2 6879357 68.08 187 78799 50 6339 97.87
B B1 6634994 67.63 178 100359 49 6041 98.07
B B2 6628209 67.63 158 93753 40 6050 98.35
Sequence reads were aligned to the reference genome and to the de novo assembly of the other
isolate from the same patient (i.e., reads from A1 isolate were aligned to the de novo assembly of A2
and vice versa) to investigate genetic changes over time. The mapping reads percentage is shown in
Table 2.
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Table 2. Percentage of reads of each isolate mapping against the de novo assembly of the corresponding
longitudinal isolate’s genome and against NH44784-1996 reference genome.
Isolate Reads Longitudinal Isolatede novo Assembly
Mapping Reads vs
de novo Assembly (%)
Mapping Reads vs
NH44784-1996 (%)
A1 A2 96.49 52.37
A2 A1 97.31 46.27
B1 B2 98.78 83.08
B2 B1 96.73 82.98
Since a high number of mapping reads was obtained between the de novo assemblies (range:
96.49–98.78%), this approach allowed us to detect almost all the variants between longitudinal isolates.
Differently, carrying out the analysis by only mapping the reads against the reference genome, these
variants would not have been considered, as the lower number of mapping reads suggests.
2.1. Variant Analysis
To take into account the possibility of calling false positive variants within the same patient over
time, the sequencing reads of A1 and B1 isolates were mapped on the genome assembly of A2 and B2
respectively, and vice versa, and only the intersection of the two groups of variants was taken into
consideration. A total of 187 variants was identified in patient A genomes, while a total of only eight
was identified in genomes from patient B as shown in Table 3. The majority of genetic alterations were
represented by SNPs. Moreover, the greater number of SNPs in patient A genomes (85%) is due to
transitions and not transversions (mean ratio: 5.8), which is typical of hypermutators.
Table 3. Genetic variants found in each genome, by type (SNPs, indel—transitions, transversions), by
translational changes (synonymous, missense, nonsense, other) and by the predicted functional impact
(frameshift, disruptive in-frame insertion/deletion, stop gain/loss).
Analysis Comparison betweenLongitudinal Isolates
Comparison with
Reference Genome
Genome A B A1 A2 B1 B2
Total 187 8 162 70 10 42
No. SNPs 150 6 150 68 8 39
No. indel 37 2 12 2 2 3
No. Synonymous SNPs 38 3 87 43 4 24
No. Missense SNPs 89 3 53 14 4 10
No. Nonsense SNPs 5 0 0 0 0 0
No. Other SNPs 18 0 10 11 0 5
Frameshift 13 2 8 0 0 2
Disruptive in-frame insertion 1 0 0 0 0 0
Disruptive in-frame deletion 0 0 0 0 0 1
Stop gain 5 0 1 0 0 0
Stop lost 1 0 0 0 0 0
Transitions 128 2 110 43 5 24
Transversions 22 4 40 25 3 15
Transition/transversion ratio 5.8 0.5 2.75 1.72 1.66 1.6
Since a great number of variants were identified in strains from patient A, the variant analysis
was performed also against the reference genome in order to investigate variants independently. A
mean total of 116 variants were found in patient A while a mean total of only 26 were found in patient
B. As shown in Table 5, the genome of isolate A1 harboured a greater number of variants (n = 162),
particularly SNPs (n = 150), when compared to the other isolates; even twice as many SNPs than its
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longitudinal isolate A2. Moreover, 73% of A1 SNPs are due to transitions (transitions/transversions
ratio: 2.75), supporting the possibility that a hypermutation event occurred.
As shown in Table 3, among the mutations that could cause a protein loss of function, frameshift
mutations are the majority followed by stop gain mutations. In particular, genomes of patient A
show a higher number of mutations when compared to genomes of patient B. A2 and B1 genomes
do not harbour mutations with a predicted high impact on protein function, since the missense SNPs
have all been annotated as having a moderate impact; the B2 genome harbours only three mutations,
while frameshift mutations are the majority in the A1 genome. Gene products affected by mutations
identified through comparison between longitudinal isolates are summarized in the Supplementary
material (Table S1).
The list of genes presenting variants, divided by functional classes according to the protein
function as reported on UniProt database, is shown in Table 4. In genomes from patient A, in particular
in A1 genome, the majority of genes presenting variants are involved in metabolism (39%), followed by
genes involved in transcription and translation (12%) and transporter proteins encoding genes (12%).
Table 4. List of gene-presenting variants, grouped by functional class. “Other” includes membrane
protein, AsmA family protein, Tol-Pal system protein TolB.
Analysis Comparison betweenLongitudinal Isolates Comparison with Reference Genome
Functional Category A B Total A1 A2 B1 B2 Total
Metabolism 66 0 66 49 18 3 4 74
Transcription and translation 21 1 22 13 3 1 4 21
Virulence, disease and defence 5 0 5 2 4 0 0 6
Hypothetical protein 34 2 36 4 1 2 3 10
Transporter 21 3 24 18 6 0 3 27
Iron acquisition and
metabolism 10 0 10 6 1 0 1 8
Stress response 2 0 2 1 1 0 0 2
DNA repair 2 0 2 0 3 0 0 3
Antibiotic resistance 7 0 7 5 3 0 0 8
Mobile genetic elements 0 0 0 0 0 0 0 0
Other 3 0 3 4 0 0 0 4
Total 171 6 177 102 40 6 15 163
2.2. Genetic Basis of Hypermutation
Since we suspected that a hypermutation event occurred in A1 isolate, the occurrence of genes
involved in DNA repair was investigated in all four genomes. All clinical isolates differed from
the reference genome because they harboured two copies of the mutL gene; they lacked superoxide
dismutase genes sodA, sodB, sodC and DNA repair gene radC; and they had only one copy of nucleotide
excision repair genes uvrA and uvrB. Moreover, the isolates coming from patient B presented an extra
copy of uvrD. Genes involved in DNA repair in each clinical isolate and in the reference strain are
summarized in the Supplementary material (Table S2).
Furthermore, gene sequences were thoroughly examined and a 95 nucleotides deletion that
translated to a 36 amino acids gap was found in A1 mutS gene (reference locus tag NH44784_RS30630).
No other mutations in DNA repair genes were found in any other genome. The mutation of mutS
might explain the higher rate of SNPs found in A1, thus defining this isolate as a hypermutator.
2.3. Mobile Genetic Elements
The presence of mobile genetic elements such as phages, plasmids, integrative and conjugative
elements (ICEs), integrative and mobilizable elements (IMEs), and cis-mobilizable elements (CIMEs),
was investigated. For phages research, only complete regions were considered. As shown in Table 5,
Pathogens 2020, 9, 72 5 of 10
Burkholderia sp. phages (KS9, Bcep176, BcepMu, KS14) were identified in all genomes. In addition, A2
also carries phages 118970 and YMC11/02/R656 from Salmonella sp. and Pseudomonas sp. respectively.
Table 5. Intact prophage regions, ICEs and IMEs found in each genome. Length of the regions is
indicated in Kbp.
Mobile Elements A1 A2 B1 B2
PHAGE_Burkho_KS9_NC_013055 21 21 - -
PHAGE_Burkho_Bcep176_NC_007497 46.7 39 18.6 24.6
PHAGE_Salmon_118970_sal3_NC_031940 - 31.6 - -
PHAGE_Pseudo_YMC11/02/R656_NC_028657 - 29.3 - -
PHAGE_Burkho_BcepMu_NC_005882 - - 40.2 40.9
PHAGE_Burkho_KS14_NC_015273 - - 31.7 -
PHAGE_Aeromo_vB_AsaM_56_NC_019527 - - - -
PHAGE_Synech_S_CBS1_NC_016164 - - - -
ICEs 93 227 - -
IMEs - - 15.6 15.6
ICEs were detected in isolates from patient A. In A1, we found one putative ICE containing
genes related to Type 4 Secretion System (T4SS), bicyclomycin resistance and iron metabolism. A2
presented one putative ICE-containing gene related to T3SS, multidrug resistance, motility, virulence
and metabolism. Both B1 and B2 presented the same putative IME-containing genes related to
multidrug resistance.
Although plasmids were not found, the presence and variation of phages, ICEs and IMEs illustrates
the potential ability of A. xylosoxidans to carry genetic and transferable elements that could contribute
to the dissemination/acquisition of microbial functions.
2.4. Phenotypic Features
To investigate possible phenotypic variations within the same host over time that might be related
to hypermutation, we evaluated features such as growth, virulence and antibiotic resistance, which are
known to undergo modifications during bacterial adaptation. As shown in Figure 1, no significant
changes in terms of growth rate and adhesion ability occurred in the isolates from the two patients.
However, we measured a strong protease activity in the culture supernatant of A1 isolate, that was
significantly higher in comparison to strain A2. No such variation was observed between the isolates
from patient B. As concerns antibiotic susceptibility, only A1 strain showed increased resistance to
meropenem (MIC > 8 mg/L) [11].
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Figure 1. Growth rate (A), biofilm formation (B) and protease activity (C) of A. xylosoxidans isolates.
Growth rate was calculated from 24 h growth curves in LB m dium (A). Adhesion was measured by
crystal violet staining of surface-attached bacteria divided by A600 of non-attached bacteria (B). Protease
activity was measured in culture supernatant by azocasein assay. Protease activity is expressed as
enzymatic units per ml (C). Each value represents the mean ± SEM of three experiments. Statistical
analysis was performed by t test, ** p < 0.01.
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3. Discussion
By sequencing and analysing the genomes of longitudinal isolates of A. xylosoxidans collected
from two infected CF patients, we have identified different adaptive mechanisms of A. xylosoxidans to
survive in a hostile environment like the CF lungs.
Two isolates were longitudinally collected from each patient with an interval of 3 years in patient
A and 6 years in patient B. During this time, both patients were chronically infected. In addition to
the standard comparison with a reference strain, we compared each A. xylosoxidans genome with its
longitudinal isolate in order to study genomic variation avoiding biases linked to the choice of the
reference genome. In all genomes, the majority of genes presenting variants are involved in metabolism,
as previously shown in other studies [7], followed by genes involved in transcription and translation
and transporter proteins encoding genes. Metabolic regulation, gene expression and trade-off are
evidently major targets of adaptation, probably enabling a physiological adaptive response through
changes in regulatory genes [12,13].
When mutations accumulate at a high rate throughout the genome, we are usually in the presence
of so-called hypermutators. Hypermutation arises through mutations that disrupt the methyl-directed
mismatch repair (MMR) system, and mutS inactivation is the most widespread defect [14]. Although a
previous study reported the finding of possible A. xylosoxidans hypermutable isolates in a CF patient [7],
this conclusion was weakened by the absence of mutations in the MMR genes. On the contrary, in
this study we identified an isolate (namely A1) that not only presents a high number of SNPs mainly
due to transitions but also carries a large deletion in mutS gene, thus clearly defining this isolate as
a hypermutator.
While this suggests the co-evolution of sub-populations from an original infecting strain in
patient A, isolates of patient B seem to represent a situation of longitudinal microevolution. Both
evolutionary mechanisms—hypermutation and microevolution—enabled long-term adaption in CF
lungs, although it has been previously suggested that high mutation rates offer bacterial advantages
in pathogenesis. In fact, hypermutation has been credited with facilitating the phenotypic changes
and clonal diversification characteristic of P. aeruginosa adaptation to the CF lung environment [15,16].
Furthermore, MMR-deficient hypermutators are overrepresented in populations of various other
pathogenic bacteria such as Escherichia coli, Salmonella spp., P. aeruginosa and Staphylococcus aureus [17].
Populations that are rapidly adapting to new or changing environments usually provide opportunities
for hypermutable genotypes to rapidly spread beneficial mutations. However, the emergence of
hypermutators does not always accelerate adaptive evolution. It has also been shown that hypermutator
populations do not always produce greater fitness gains than DNA-repair proficient populations [18].
A mutator might rise transiently to high frequency and then be eliminated if the non-mutator type
produces an even more beneficial mutation than that produced by the mutator [19]. For instance, the
high protease secretion as well as meropenem resistance observed in the hypermutator isolate A1 could
have been a result of adaptation to a stressful condition, but probably did not produce a greater fitness.
Indeed, non-mutator strain A2 was isolated 3 years later, suggesting that even a low mutation rate was
sufficient to generate beneficial mutations, similarly to the microevolution observed in patient B.
In conclusion, we report the occurrence of hypermutation as a mechanism that could be involved
in A. xylosoxidans long-term infection of CF lungs. Further studies, possibly on a larger scale, will be
needed to understand the frequency and benefits of A. xylosoxidans hypermutability.
4. Materials and Methods
4.1. Bacterial Isolates
Four clinical isolates of A. xylosoxidans were collected from two patients followed at Rigshospitalet
in Copenhagen, Denmark. The use of the stored bacterial isolates was approved by the local
ethics committee at the Capital Region of Denmark (Region Hovedstaden) with registration
number H-4-2015-FSP. Two isolates were longitudinally collected from each patient: in 2005
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and 2008 from patient A, and in 2008 and 2014 from patient B. Susceptibility to the following
antibiotics was tested: amoxicillin + clavulanic acid, ampicillin, aztreonam, ceftazidime, ceftriaxone,
cefuroxime, chloramphenicol, ciprofloxacin, colistin, imipenem, meropenem, moxifloxacin, penicillin,
piperacillin + tazobactam, sulfamethoxazole, sulfamethoxazole + trimethoprim, tetracycline,
tobramycin, trimethroprim.
4.2. Library Preparation and Whole-Genome Sequencing
DNA was purified from over-night liquid cultures of single colonies using the DNEasy Blood
and Tissue Kit (Qiagen). Libraries were made with Nextera XT and sequenced on an Illumina
MiSeq using the v2 250 × 2 kit [20]. This project has been deposited at EMBL under the accession
PRJEB35058. Sequence data can be found with the experiment accession numbers ERX3614542 (strain
A1), ERX3614543 (strain A2), ERX3614548 (strain B1), and ERX3614549 (strain B2). The pair end
sequencing yielded 3,842,110 reads for isolate A1; 2,947,162 reads for isolate A2; 2,806,776 reads for
isolate B1; and 2,847,706 reads for isolate B2. As a reference genome sequence, the annotated genome
A. xylosoxidans NH44784-1996 was used, which belongs to a strain isolated from sputum of a CF patient
followed at Copenhagen CF Center in 1996 [10].
4.3. De Novo Assembly
The quality of the raw reads was assessed using FastQC v0.11.7, and adapter and quality trimming
was performed accordingly following the illuminaclip, leading, trailing, slidingwindow and milen steps
of Trimmomatic v0.36 [21] (Illuminaclip:adapter_file.fa:2:30:20 leading:3 trailing:3 slidingwindow:4:20
minlen:50). Sequence reads from each isolate were de novo assembled using the SPAdes v3.11.1 [22]
assembly toolkit using the careful option. The quality of the de novo assemblies was evaluated using
QUAST QC v5.0.0 [23] and by mapping the reads on the corresponding assembly using Bowtie 2
v2.3.4.1 [24] (coverage range: 97.87–98.35%); Samtools v1.9 [25] was used to obtain sorted bam files;
Bedtools v2.27.1 [26] was used to obtain the per base sequence coverage; and Qualimap v2.2.1 [27]
was used to obtain mapping and coverage statistics. All the de novo assemblies were annotated using
Prokka v1.13 [28]. Genotypic relatedness was verified by checking core genome similarities obtained
using the Harvest-OSX64-v1.1.2 suite [29].
4.4. Variant Analysis
Two types of variant analysis were carried out by aligning sequence reads to the A. xylosoxidans
NH44784-1996 reference genome and to the de novo assembly of the longitudinal isolate from the same
patient (reads from isolate 1 were aligned to the de novo assembly of isolate 2 from the same patient
and vice versa) using Bowtie 2 v2.3.4.1. Sorted bam files were obtained using Samtools v1.9 and the
MarkDuplicates tool from Picard v2.17.10 was used to mark duplicates. Finally, HaplotypeCaller of the
Genome Analysis Toolkit (GATK) v4.0.6.0 [30] was used with the sample-ploidy option set to 1 to call
SNPs and indels. In order to annotate the variants and predict their functional effects, SnpEff v4.3t [31]
toolbox was used employing custom-built SnpEff databases obtained starting from fasta sequences
and gff annotations of the genomes. Only variants supported by a minimum of 20 reads were retained.
For the analysis performed between the isolates, an ulterior step was performed in order to
consider only true variants and discard false positives. Starting from the vcf files, the variants’ positions
were extracted, and a bed file was created in order to extract from the de novo assembly the sequences
containing the variant and a flanking region of 75 bp in each direction using Bedtools v2.27.1, thus
obtaining 151 bp sequences. These were then mapped on the de novo assembly of the corresponding
longitudinal isolate using Bowtie 2 v2.3.4.1 with the option end-to-end and setting the mismatch
penalty to 0. Moreover, only the reads that mapped where a variant was called in the longitudinal
isolate were kept. Finally, the occurrences of transitions and transversions were counted and the
transitions/transversions ratio was calculated.
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4.5. Mutator Genes Analysis
The genetic basis of hypermutation was investigated from whole genome sequencing data
by analysing genes involved in this phenomenon [32]. The following genes present in the
reference NH44784-1996 were considered: RS17415/PfpI, RS20390/PfpI, RS30630/MutS, RS06175/MutL,
RS27975/RadA, RS21930/Rad50, RS11590/UvrA, RS27010/UvrB, RS31300/UvrC, RS27580/UvrD, and
RS09700/UvrD.
4.6. Mobilome Analysis
The Phage Search Tool Enhanced Release (PHASTER) [33] was used in order to identify and
annotate prophage sequences. The presence of plasmids was investigated in two ways. First,
PlasmidFinder v2.0 [34] was used on the de novo assembled genomes. Moreover, the plasmidSPAdes
pipeline was used on the whole genome sequencing dataset, and the DNA sequences of the putative
plasmids were then blasted against the non-redundant (nr) BLAST database [35]. The presence
of integrative and conjugative elements (ICEs), integrative and mobilizable elements (IMEs), and
cis-mobilizable elements (CIMEs) was studied using the ICEfinder tool based on the ICEberg 2.0
database of bacterial integrative and conjugative elements [36].
4.7. Growth Curves
Bacterial strains were plated on LB agar and incubated at 37 ◦C for 24–48 h. One to two colonies
were inoculated in 10 mL LB medium shaking at 37 ◦C overnight. OD600 was measured using a
spectrophotometer, cultures were diluted to 0.05 OD/mL in LB medium and 150 µL/well were incubated
in a 96-well plate for 20–24 h shaking at 37 ◦C. Using an automated plate reader, A600 was measured
every 20 min. Growth rate was calculated using GraphPad Prism software.
4.8. Adhesion Assay
Bacterial strains were plated on LB agar and incubated at 37 ◦C for 24–48 h. One to two colonies
were inoculated in 10 mL LB medium shaking at 37 ◦C overnight. OD600 was measured using a
spectrophotometer, cultures were diluted to 0.05 OD/mL in LB medium and 150 µL/well were incubated
in a 96-well plate for 20–24 h at 37 ◦C. After measuring A600, wells were washed twice with water to
remove unattached cells, and surface-attached cells were stained with 0.1% crystal violet solution for
15 min. Wells were rinsed and washed three times with water, then dried for 1–2 h. Thirty percent
acetic acid was added, incubated at room temperature for 15 min, and A590 was measured. Thirty
percent acetic acid was used as blank.
4.9. Protease Activity Measurement
A. xylosoxidans strains were plated on LB agar and incubated at 37 ◦C for 24–48 h. One to two
colonies were inoculated in 10 mL LB medium shaking at 37 ◦C for 16 h. OD600 was measured and
cultures were diluted to 0.1 OD/mL in 10 mL of LB medium. After shaking at 37 ◦C for 16 h, cultures
were diluted to 1 OD/mL and centrifuged at 7000× g for 30 min at 4 ◦C. Supernatants were collected
and sterile-filtered. Protease activity in culture supernatants was determined by azocasein assay as
previously described [37]. Briefly, 350 µL reaction mixture containing 0.1 M Tris-HCl, pH 8.0, and 1%
azocasein (Sigma-Aldrich, previously resuspended in 0.5% NaHCO3) was added to 150 µL supernatant
and incubated at 37 ◦C for 20 min shaking. After the addition of 1 mL 7% ice-cold perchloric acid, the
solution was centrifuged. One-hundred-and-fifty microlitres of 10 N sodium hydroxide were added to
the clear supernatant and OD430 was measured. One protease unit was calculated as the amount of
enzyme producing an increase of 0.1 OD per hour.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/9/2/72/s1, Table
S1: List of gene products affected by loss of function mutations in each genome versus the genome of its longitudinal
isolate; Table S2: Presence of genes involved in DNA repair in each clinical isolate and in the reference strain.
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